Published in Hepatitis Weekly, July 3rd, 2006
Novartis and HGS will copromote Albuferon (albumin interferon alfa-2b) in the U.S., while Novartis will have exclusive rights to market and promote it in the rest of the world. Phase III trials are expected to begin by the end of 2006.
Under the terms of the agreement, HGS will receive an upfront payment of US$45 million, with milestones payable at specific stages of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.